{"id":"azd9291-dosing","safety":{"commonSideEffects":[{"rate":"55","effect":"Diarrhea"},{"rate":"35","effect":"Rash"},{"rate":"25","effect":"Nausea"},{"rate":"15","effect":"Vomiting"},{"rate":"15","effect":"Stomatitis"},{"rate":"20","effect":"Decreased appetite"},{"rate":"15","effect":"Fatigue"},{"rate":"5","effect":"QT prolongation"}]},"_chembl":{"chemblId":"CHEMBL3604943","moleculeType":"Small molecule","molecularWeight":"497.60"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"AZD9291 (osimertinib) covalently binds to cysteine-797 in the ATP-binding pocket of mutant EGFR, providing sustained inhibition of oncogenic signaling. It is specifically designed to overcome resistance conferred by the T790M mutation that emerges during treatment with first- and second-generation EGFR inhibitors. The drug's selectivity for mutant over wild-type EGFR reduces toxicity to normal tissues.","oneSentence":"AZD9291 is a third-generation EGFR tyrosine kinase inhibitor that irreversibly binds to and inhibits mutant EGFR, including T790M resistance mutations, while sparing wild-type EGFR.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:03:14.108Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer with EGFR T790M mutation after progression on first- or second-generation EGFR inhibitors"},{"name":"EGFR-mutant non-small cell lung cancer (first-line treatment)"}]},"trialDetails":[{"nctId":"NCT06538038","phase":"","title":"Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients","status":"RECRUITING","sponsor":"PrECOG, LLC.","startDate":"2024-09-17","conditions":"Non Small Cell Lung Cancer, Epidermal Growth Factor Receptor Gene Mutation, Stage III Lung Cancer","enrollment":538},{"nctId":"NCT07461727","phase":"PHASE1","title":"An Open-Label, Single-Arm, Dose-Escalation Phase I Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of EDB-102 in Patients With EGFR L858R-Mutant, Third-Generation TKI-Resistant Advanced Non-Small Cell Lung Cancer With Liver Metastases","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2026-02-10","conditions":"Non-Small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer, Liver Metastases","enrollment":15},{"nctId":"NCT04988295","phase":"PHASE3","title":"A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2021-11-17","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":776},{"nctId":"NCT02143466","phase":"PHASE1","title":"AZD9291 in Combination With Ascending Doses of Novel Therapeutics","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2014-08-05","conditions":"Advanced Non Small Cell Lung Cancer","enrollment":344},{"nctId":"NCT07285148","phase":"PHASE1, PHASE2","title":"A Study to Evaluate ANS014004 in Combination With EGFR-TKI in Non-Small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Beijing Pearl Biotechnology Limited Liability Company","startDate":"2026-06","conditions":"Non-Small Cell Lung Cancer, EGFR Mutation, Metastatic Lung Cancer","enrollment":253},{"nctId":"NCT02197234","phase":"PHASE1","title":"Study to Assess the Effect of AZD9291 on the Blood Levels of Simvastatin in Patients With EGFRm+ NSCLC","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-12-22","conditions":"Non Small Cell Lung Cancer","enrollment":52},{"nctId":"NCT02157883","phase":"PHASE1","title":"Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of AZD9291, in Patients With EGFR Positive Non-small Cell Lung Cancer. Patients Will be Chosen From Those Who Have Already Been Prescribed an EGFR TKI Medicine (Such as Iressa or Tarceva)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-11-06","conditions":"Advanced Non Small Cell Lung Cancer, Advanced (Inoperable) Non Small Cell Lung Cancer","enrollment":39},{"nctId":"NCT02099058","phase":"PHASE1","title":"A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Participants With Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2014-01-15","conditions":"Advanced Solid Tumors Cancer","enrollment":237},{"nctId":"NCT02664935","phase":"PHASE2","title":"National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Birmingham","startDate":"2015-05","conditions":"Non-Small Cell Lung Cancer, Carcinoma, Squamous Cell, Adenocarcinoma","enrollment":423},{"nctId":"NCT03755102","phase":"EARLY_PHASE1","title":"A Pilot Study of Dacomitinib With or Without Osimertinib for Patients With Metastatic EGFR Mutant Lung Cancers With Disease Progression on Osimertinib.","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2018-11-21","conditions":"EGFR Gene Mutation, Lung Cancer, Lung Cancer Metastatic","enrollment":17},{"nctId":"NCT04141644","phase":"PHASE1","title":"Safety and Efficacy of Combination Osimertinib and Ipilimumab in Patients w EGFR Mutated NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Utah","startDate":"2020-08-20","conditions":"Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor (Disorder)","enrollment":24},{"nctId":"NCT06692491","phase":"PHASE2","title":"Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS","status":"NOT_YET_RECRUITING","sponsor":"Peking University Shenzhen Hospital","startDate":"2025-01-01","conditions":"Rare Tumour","enrollment":200},{"nctId":"NCT06362980","phase":"PHASE1","title":"A Study With BPI-1178 and Osimertinib in Advanced Non-small Cell Lung Cancer Patients With EGFR Mutations","status":"RECRUITING","sponsor":"National Cancer Center, China","startDate":"2024-05-22","conditions":"NSCLC","enrollment":20},{"nctId":"NCT06032936","phase":"PHASE1","title":"BBP-398 in Combination With Osimertinib in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutations","status":"TERMINATED","sponsor":"LianBio LLC","startDate":"2023-07-27","conditions":"NSCLC","enrollment":4},{"nctId":"NCT02997501","phase":"PHASE3","title":"T790M Plasma Testing Methodology Comparison and Clinical Validation","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2016-12-23","conditions":"Lung Cancer","enrollment":256},{"nctId":"NCT03446417","phase":"PHASE1","title":"A Study of ZN-e4 in Subjects With Epidermal Growth Factor Receptor Mutated Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Zeno Pharmaceuticals, Inc.","startDate":"2018-04-20","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":34},{"nctId":"NCT02163733","phase":"PHASE1","title":"Study to Determine the Effect of Food on the Blood Levels of AZD9291 Following Oral Dosing of a Tablet Formulation in Patients With Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-11-14","conditions":"Advanced Non Small Cell Lung Cancer, Advanced (Inoperable) Non Small Cell Lung Cancer","enrollment":38},{"nctId":"NCT02923947","phase":"PHASE1","title":"Study to Assess Osimertinib in Patients w/ Adv Solid Tumours & Normal Kidney Function or Severe Kidney Impairment","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2017-05-04","conditions":"Solid Tumours","enrollment":16},{"nctId":"NCT03455829","phase":"PHASE1, PHASE2","title":"G1T38, a CDK 4/6 Inhibitor, in Combination With Osimertinib in EGFR-Mutant Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"G1 Therapeutics, Inc.","startDate":"2018-03-29","conditions":"Carcinoma, Non-Small-Cell Lung, Lung Cancer, Non-small Cell Lung Cancer","enrollment":30},{"nctId":"NCT04798638","phase":"PHASE1","title":"A Study to Assess the Effect of Food on the Pharmacokinetics of TY-9591 in Healthy Volunteers","status":"COMPLETED","sponsor":"TYK Medicines, Inc","startDate":"2021-04-30","conditions":"Healthy Volunteers","enrollment":16},{"nctId":"NCT02908750","phase":"PHASE1","title":"Study to Assess the Effect of Osimertinib (TAGRISSO™ ) on Blood Levels of Fexofenadine in Patients With EGFRm+ NSCLC","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2017-03-02","conditions":"Non Small Cell Lung Cancer","enrollment":24},{"nctId":"NCT02474355","phase":"PHASE3","title":"Real World Treatment Study of AZD9291 for Advanced/Metastatic EGFR T790M Mutation NSCLC","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-09-18","conditions":"Lung Cancer","enrollment":3017},{"nctId":"NCT02197247","phase":"PHASE1","title":"Study to Assess the Effect of Rifampicin on Blood Levels and Safety of AZD9291, in Patients With EGFRm+ NSCLC","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-12-04","conditions":"Non Small Cell Lung Cancer","enrollment":41},{"nctId":"NCT02161770","phase":"PHASE1","title":"Study to Assess the Blood Levels and Safety of AZD9291 in Patients With Advanced Solid Tumours and Normal Liver Function or Mild or Moderate Liver Impairment","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-12-22","conditions":"Solid Tumours","enrollment":30},{"nctId":"NCT02317016","phase":"PHASE1","title":"Study to Assess the Effect of AZD9291 on the Blood Levels of Rosuvastatin, in Patients With EGFRm+ Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-03-10","conditions":"Non Small Cell Lung Cancer","enrollment":44},{"nctId":"NCT02224053","phase":"PHASE1","title":"Drug-Drug Interaction Study With AZD9291 and Omeprazole in Healthy Volunteers","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-09","conditions":"Healthy Volunteer","enrollment":136}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":50,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"AZD9291 Dosing","genericName":"AZD9291 Dosing","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AZD9291 is a third-generation EGFR tyrosine kinase inhibitor that irreversibly binds to and inhibits mutant EGFR, including T790M resistance mutations, while sparing wild-type EGFR. Used for Non-small cell lung cancer with EGFR T790M mutation after progression on first- or second-generation EGFR inhibitors, EGFR-mutant non-small cell lung cancer (first-line treatment).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":2,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}